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AIM
The D2/D3 antagonist amisulpride has shown promising efﬁcacy against postoperative nausea and vomiting (PONV) at low doses.
We investigated whether intravenous amisulpride has an effect on the QTc interval in a formal Thorough QT study (TQT).
METHODS
This was a randomized, double-blind, placebo and positive-controlled, four-way crossover study. Forty healthy Caucasian and
Japanese subjects were included to receive a single administration of 5 mg and 40 mg of i.v. amisulpride or a single oral dose of
moxiﬂoxacin or placebo per period.
RESULTS
The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to
dosing to a peak of 5ms (90%CI: 2.8, 7.1ms) at 8min, decreasing to 2.1ms at 30min after dosing. The supra-therapeutic dose of
40 mg given at twice the infusion rate was associated with prolongation in ΔΔQTcF peaking at 23.4 ms (90% CI: 21.3, 25.5 ms) at
the end of infusion (8 min), returning below 10 ms within 1.5 h. Assay sensitivity was conﬁrmed; ΔΔQTcF had increased by
12.3ms (90%CI 10.1, 14.6ms) at 4 h post-dose. The PK-PD relationship revealed no differences between Caucasian and Japanese
subjects (p-value > 0.5).
CONCLUSIONS
Amisulpride has a plasma concentration-dependent effect on the QTc interval. The proposed therapeutic dose for management
of PONV does not lead to a prolongation of QTcF above the threshold of regulatory concern, while such effect could not be
excluded for the supratherapeutic dose.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Amisulpride is an atypical antipsychotic approved for the treatment of acute and chronic psychoses.
• Overdoses of amisulpride are known to have effects on cardiac repolarization and the assessment of the potential for the
drug to prolong the QT interval when administered intravenously remains to be elucidated.
• Much lower doses than those used to treat psychoses have been shown to be effective at preventing postoperative nausea
and vomiting when given intravenously.
WHAT THIS STUDY ADDS
• At the therapeutic dose of 5 mg amisulpride, the attained Cmax was comparable to the optimum plasma concentrations to
treat psychoses using higher oral doses.
• The proposed therapeutic dose of 5 mg amisulpride given over 2 min does not prolong QTc interval.
• A supratherapeutic dose of 8 times higher than the therapeutic dose infused at double the rate led to ΔΔQTcF prolonga-
tion of 23.4 ms at the end of infusion and to a Cmax concentration of 1305.44 ng ml
1, similar to the largest available oral
presentation of amisulpride.
Tables of Links
TARGETS
GPCRs [2] Voltage gated ion channels [3]
D2 receptor hERG
D3 receptor Nav1.5
LIGANDS
Amisulpride
These Tables lists key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to PHARMACOLOGY
2015/16 [2, 3].
Introduction
Amisulpride is a substituted benzamide that acts as a selective
antagonist of dopamine D2 and D3 receptors [4]. It was intro-
duced in the 1980s as an ‘atypical’ antipsychotic and has
been approved in many countries for the treatment of acute
and chronic psychoses at a dose range between 50 and
1200 mg per day, given orally or intramuscularly [5, 6]. The
overall safety proﬁle of amisulpride at its approved doses
has been assessed in numerous clinical studies with no evi-
dence of cardiac toxicity [6–8]. However, very large overdoses
of oral amisulpride have been associated with the develop-
ment of torsade de pointes (TdP) [9–13] and there is a solitary
case report in the literature suggesting that TdP may have
been caused by a low oral dose of 100 mg day1 in a patient
with a low body mass index [14].
In in vitro testing, amisulpride has been shown to have a
low potential for blockade of the cardiac hERG channel, with
a high IC50 value of approximately 100 μM for inhibition of
the repolarizing delayed rectiﬁer potassium current, IKr, and
less than 20% displacement of [3H]-astemizole binding [15].
Amisulpride has also been shown to bind to NaV1.5 and the
effects of late INa blockade ability have been suggested to
reduce the impact on QT interval due to hERG blockade [16].
QT response may differ between ethnic groups and this
may be attributable to inter-ethnic differences in the fre-
quency of variant alleles of the genes SCN5A, KCNH2,
KCNE2, KCNQ1 and KCNE1 encoding for the sodium chan-
nel NaV1.5 and four potassium channels respectively [17–19].
Recently, an intravenous (i.v.) dose of 5 mg amisulpride
was shown to be superior to placebo at preventing
postoperative nausea and vomiting [20]. As part of the clini-
cal development programme for amisulpride, we conducted
a speciﬁcally designed Thorough QT/QTc (TQT) study, in ac-
cordance with the ICH E14 guideline, in order to quantify
the effect of i.v. amisulpride on the QTc interval at the thera-
peutic dose proposed for PONVmanagement and at an eight-
fold supratherapeutic dose. Additionally, the study compared
the PK-QTc relationship in two ethnic groups: Caucasian and
Japanese.
Methods
The study was given a positive opinion by an authorized
Research Ethics Committee (NRES Committee South
Central – Berkshire B, ref: 13/SC/0496), approved by the
Medicines and Healthcare products Regulatory Authority
and registered with EudraCT (ref: 2013-002 669-20) and
ClinicalTrials.gov (ref: NCT02661594). The trial was con-
ducted at a single centre (Richmond Pharmacology Ltd, UK)
between 22 November 2013 and 31 March 2014. Its conduct
was in accordance with the principles of the Declaration of
Helsinki, current UK law and Good Clinical Practice (GCP)
guidelines. Each subject received verbal and written informa-
tion followed by signing of the Informed Consent Form (ICF)
prior to any procedures taking place.
Subjects
General eligibility of 102 subjects volunteering for participa-
tion in this study was assessed at screening, which took place
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within 21 days of the ﬁrst study drug administration. Male
and female subjects were included if they were healthy,
non-smoking, Caucasian or Japanese, aged between 20 and
45 years and had a body mass index ranging between 18
and 25 kg m2 inclusive. Subjects were excluded if they had:
(i) a medical or family history of congenital long QT syn-
drome; (ii) a clinically signiﬁcant abnormal ECG (PR consis-
tently <120 or >230 ms, QRS consistently ≥120 ms, QTcB
>430ms formales and>450ms for females, heart rate consis-
tently<45 beats min1 or>100 beats min1); (iii) if they used
any concomitant medication that impaired drug metaboliz-
ing capacity or was known to have a QT-prolonging effect;
or (iv) had any intolerance to moxiﬂoxacin or amisulpride.
Study design
This was a randomized, double-blind, placebo and positive-
controlled, four-way crossover study using features of an
adaptive study design, including the potential to add sub-
jects depending on the standard deviation obtained during
a blinded ECG review allowing the sample size to be
adapted optimally to the variability occurring in this partic-
ular trial [21]. The 40 eligible subjects were randomized to
one of four sequences of the four study treatments
(Figure 1): oral moxiﬂoxacin 400 mg (M), i.v. amisulpride
5 mg (A5), i.v. amisulpride 40 mg (A40) and i.v. normal sa-
line as a placebo (P). The four sequences (A5-A40-M-P,
A40-P-A5-M, P-M-A40-A5 and M-A5-P-A40) were balanced
for period and preceding treatment (Williams squares). Each
treatment period consisted of a placebo baseline day (Day
1), followed by the treatment day (Day 1). A washout
period of at least seven days separated treatment periods.
ECGs and blood samples for PK analysis were taken at the
same time points on Days 1 and 1 of every period.
Subjects attended for a follow-up visit scheduled 7–14 days
after the last dose.
Intravenous study treatments were fully blinded and
administered from two syringe drivers starting at the same
time, one infusing 2.5 ml over 2 min, the other infusing
20 ml over 8 min. The 5 mg amisulpride dose was given as
2.5 ml of 2 mg ml1 amisulpride over 2 min in parallel with
normal saline in the other syringe driver. The 40 mg
amisulpride dose was given as 20 ml of 2 mg ml1
amisulpride over 8 min in parallel with normal saline in
the other syringe driver. For the placebo treatment, both
syringe drivers contained normal saline. Moxiﬂoxacin was
given unblinded as a single, commercially-sourced, 400 mg
oral tablet, preceded on Day 1 by a single, inactive
moxiﬂoxacin-placebo tablet.
ECG assessment and QTc evaluation
Twelve-lead ECGs were recorded using a MAC1200® ECG re-
corder (GE Healthcare, Buckinghamshire, UK) and stored
electronically on the Medical MUSE® information system
(GE Healthcare, Buckinghamshire, UK). ECG recordings were
made at the following time points: pre-dose, 2, 8 and 30 min,
1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 h post-dose of each treatment
period. Before any ECG recording, the subjectsmaintained an
undisturbed supine resting position for at least 10 min and
avoided postural changes during the ECG recordings. At each
time point, the ECGs were recorded in triplicate, to reduce
Figure 1
Study ﬂow chart
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variance and improve the precision of measurement. Each
ECG lasted 10 s. The triplicates were performed at one-
minute intervals over 3 min. The QT interval, RR interval
and heart rate, PR interval and QRS duration, the presence
or absence of U-waves, quantitative and qualitative ECG
variations were assessed by cardiologists with extensive ex-
perience of manual on-screen over-reading with electronic
callipers using the commercially available MUSE® in its lat-
est version to correct any implausible readings presented by
the automated process. During hospitalization, subjects
were served breakfast before dosing, lunch and dinner with
similar nutritional composition at approximately 6 h and
12 h post-dose, respectively. On baseline and treatment
days, breakfast was identical across all periods and was
served 1 h and completed 30 min prior to allocated dose
administration.
Statistical analysis
The primary analysis was based on the crossover design of the
study and used the change from average baseline of QTcF of
the baseline day. For each time point, a linear mixed effects
model with sequence, period, gender and race and treatment
as ﬁxed effects and baseline as covariate was adapted, with
subject (nested in sequence) as a random effect. Two-sided
90% conﬁdence intervals for the difference between each
dose of amisulpride and placebo (safety) and moxiﬂoxacin
and placebo (assay sensitivity) were derived. All subjects in
the safety dataset who had valid ECG data for at least one
post-dosing time point during periods 1–4 were included in
the primary analysis set. To show assay sensitivity, a
Hochberg procedure was applied to the results of the 2, 3
and 4 h time points of the difference between placebo and
positive control (moxiﬂoxacin). Baseline was calculated from
the Day1 values of the respective period. Two types of base-
line were used: the averaged baseline for the primary analysis
and a time-matched one for a secondary analysis. Baseline
ECGs were scheduled to match the on-treatment clock time
points for each treatment period. Categorical analyses were
performed to determine the number of subjects per treatment
regimen and time who had values >450 ms as well as an in-
crease from baseline QTc interval ≥30 ms and ≥60 ms by gen-
der. Furthermore, a linear concentration response model was
ﬁtted to all QTcF data in the two amisulpride groups. The
placebo-corrected change from average baseline (ΔΔQTcF)
was used as a dependent variable. Themodel had a ﬁxed inter-
cept and slope but random intercepts only. The absence of
hysteresis was conﬁrmed graphically. For each dose group
the placebo-corrected change from baseline in QTcF was plot-
ted over time as well as the drug concentration of the respec-
tive dose group. If maximum ΔΔQTcF was delayed compared
with the respective plasma concentration by at least 1 h, a
model with an additional effect compartment was to be used
to replace the mixed effects model described above. However,
this replacement was only to be done if the maximal effect of
amisulpride (point estimate) as estimated in the primary
analysis was 5 ms or above. To assess differences between
the Caucasian and Japanese subjects, a factor ethnicity and
its interaction with concentration were added to the model
and tested against a null hypothesis of no effect. The models
were graphically presented by a regression line together with
a two-sided 90% conﬁdence region. For the model with eth-
nicity, separate regression lines for Caucasians and Japanese
were given.
The appropriateness of a linear model was assured by
inspecting the goodness of ﬁt, for example by looking at nor-
mal QQ plots for the residuals and plots of the residuals over
predicted values. If there was an indication that a linear
model was inappropriate, the nonlinearity detected was to
be taken into account by an appropriate transformation of
the concentration values (e.g., log(conc/lloq)) or by the use
of an appropriate nonlinear model.
Pharmacokinetic assessments
Pharmacokinetic samples were taken over a 24 h period on
Day 1 of each period. Timings for pharmacokinetic blood
sampling were coincident with ECG assessment time points.
Plasma samples for determination of amisulpride concentra-
tion were analysed by Quotient BioAnalytical Sciences. A val-
idated liquid chromatography/tandem mass spectrometry
(LC/MS/MS) method with liquid–liquid extraction has been
used, developed and satisfactorily validated for the measure-
ment of amisulpride in human plasma over the calibration
range 2–2000 ng ml1 with a lower limit of quantiﬁcation of
2 ng ml1. Validation procedures were based on those
outlined in the ‘Guideline on Bioanalytical Method
Validation’ [22].
Chromatographic separation was performed through a
Waters CSH C18 (1.7 μm, 2.1 × 50 mm, Waters Corporation,
Milford, Massachusetts, USA) analytical column at 40°C, with
a mobile phase consisting of 10 mM ammonium formate in
0.2% formic acid. The ﬂow rate was 0.6 ml min1, and the
total run time was 3 min. Detection and quantiﬁcation were
performed by mass spectrometry using a Sciex API5000
mass spectrometer (AB Sciex LLP, Framingham, Massachu-
setts, USA).
The precision and accuracy (expressed as the coefﬁcient of
variation (% CV) and as the relative error (% RE) respectively)
of the method was found to be within the target limits of
±20% at the lower limit of quantiﬁcation and within ±15%
at all other concentrations. The recovery of amisulpride
from human plasma was reproducible and acceptable. The
selectivity of the method was found to be satisfactory with
no endogenous interference which may adversely affect
the analysis. Amisulpride was found to be stable in human
plasma for up to 28 h at room temperature, after four
freeze–thaw cycles from 20°C and for up to 119 days
stored at nominally 20°C. Amisulpride was found to be
stable in whole human blood for up to 2 h at room tem-
perature, at 30°C and at 37°C. No signiﬁcant matrix effect
was observed, and the method was found satisfactory for
the analysis.
Pharmacokinetic analyses were performed using non-
compartmental methods using SAS™ version 9.2 (SAS
Institute, Buckinghamshire, UK).
Pharmacokinetic parameters were calculated using non-
compartmental analysis of the plasma concentration–time
data: observed maximum plasma concentration (Cmax), time
to Cmax (tmax), apparent terminal half-life (t½) calculated by
0.693/λz, area under the plasma concentration–time curve
from zero to time t of the last measured concentration (Clast)
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above the limit of quantiﬁcation (AUC0–t) calculated by the
linear up-log down trapezoidal method and area under the
plasma concentration–time curve from zero to inﬁnity
(AUC0–∞) calculated by AUC0–t + AUCt–∞, where AUCt–∞ is
the residual area under the plasma concentration vs. time
curve, extrapolated by Clast/λz.
Safety assessments
All adverse events (AEs) were continuously monitored
throughout the study from the date informed consent was
signed until the end of each subject’s participation. The in-
tensity and potential relationship with the study drugs of
each of the reported AEs were assessed. Vital signs, blood
pressure (systolic and diastolic) and heart rate were regularly
measured during the study. Laboratory investigations includ-
ing haematology, biochemistry and urinalysis were per-
formed during the screening period, Day 2 and follow-up.
Any clinically relevant abnormalities were reported as AEs.
Results
Subject characteristics and disposition
Subject disposition and characteristics are summarized in
Table 1 and in Figure 1. Of the 40 subjects enrolled, 23
subjects were Caucasian (12 females and 11 males) and 17
were Japanese (5 females and 12 males). Thirty-eight subjects
completed the study, two subjects being withdrawn. One sub-
ject received 5 and 40 mg amisulpride before withdrawal due
to non-compliance with the protocol and one received
moxiﬂoxacin before choosing to withdraw. All subjects were
included in all the analysis sets, with the exception of the
subject withdrawn due to protocol non-compliance, who
was included in the safety set but not in the PK set.
Effect of amisulpride 5 mg and 40 mg on QTcF
The ΔQTcF proﬁles (Figure 2A) of 5mg and 40mg amisulpride
and moxiﬂoxacin demonstrated a dose-dependent effect of
amisulpride onQTcF at early time points. At the end of the in-
fusion of amisulpride 5mg, ΔQTcF was slightly changed, with
a difference relative to baseline of 0.9ms (90%CI: 1.1, 3.0ms)
at 2 min. At 8 min ΔQTcF increased by 2.4 ms (90% CI: 0.6,
4.2 ms). Following administration of a 40 mg dose, ΔQTcF
increased 5.2ms (90%CI: 3.2, 7.3ms) at 2min and had a peak
value of 20.8 ms (90% CI: 19, 22.6 ms) at 8 min, the end of
infusion for the higher dose. The upper bound of the conﬁ-
dence interval remained above 10 ms at 30 min and 1 h
(16.9 and 10.5 ms, respectively). The ΔQTcF proﬁle of
amisulpride 40 mg returned to levels similar to baseline after
2 h. Following administration of placebo, ΔQTcF showed a
maximum shortening at 4 h, with a difference relative to
Table 1
Summary of subjects’ characteristics
A5-A40-M-P (n = 10) A40-P-A5-M (n = 11) M-A5-P-A40 (n = 10) A5-A40-M-P (n = 9)
Age (years) Mean (SD) 27.50 (4.22) 26.82 (4.24) 30.20 (8.07) 27.44 (4.93)
Range 21–33 21–34 21–45 23–38
Gender, n (%) Female 4 (40.0) 5 (45.5) 4 (40.0) 4 (44.4)
Male 6 (60.0) 6 (54.5) 6 (60.0) 5 (55.6)
Ethnicity, n (%) Caucasian 6 (60.0) 6 (54.5) 6 (60.0) 5 (55.6)
Japanese 4 (40.0) 5 (45.5) 4 (40.0) 4 (44.4)
Height (cm) Mean (SD) 170.10 (8.27) 172.55 (6.79) 171.90 (6.37) 171.44 (9.30)
Range 158–182 161–180 162–181 157–182
Mean (SD) Caucasian 170.67 (9.11) 176.5 (4.09) 172.17 (7.49) 173.6 (9.84)
Range 162–182 169–180 162–181 157–182
Mean (SD) Japanese 169.25 (8.06) 167.8 (6.53) 171.5 (5.26) 168.75 (9.18)
Range 158–176 161–178 164–176 161–182
Weight (kg) Mean (SD) 65.24 (8.43) 63.42 (10.73) 64.22 (9.14) 66.27 (9.40)
Range 49.1–79.5 46.9–76.8 50.0–79.1 52.5–83.3
Mean (SD) Caucasian 65.93 (10.64) 71 (7.34) 66.13 (8.79) 70.58 (9.62)
Range 49.1–79.5 59.7–76.8 52–79.1 56.3–83.3
Mean (SD) Japanese 64.2 (4.71) 54.32 (5.52) 61.35 (10.16) 60.88 (6.53)
Range 57.2–67.4 46.9–61.5 50–72 52.5–67.2
BMI (kg m2) Mean (SD) 22.49 (1.83) 21.19 (2.51) 21.66 (2.26) 22.46 (1.74)
Range 18.5–24.3 18.1–24.8 18.5–24.6 19.3–25.1
Mean (SD) Caucasian 22.53 (2.32) 22.8 (2.31) 22.25 (2.04) 23.3 (1.17)
Range 18.5–24.3 18.4–24.8 19.1–24.6 22.2–25.1
Mean (SD) Japanese 22.43 (1.01) 19.26 (0.7) 20.78 (2.57) 21.4 (1.9)
Range 21.4–23.6 18.1–19.9 18.5–23.2 19.3–23.2
A5: amisulpride, 5 mg; A40: amisulpride, 40 mg; BMI: body mass index; M: moxiﬂoxacin, 400 mg; P: placebo; SD: standard deviation
Effect of intravenous amisulpride on QTc interval
Br J Clin Pharmacol (2017) 83 339–348 343
baseline of 4.9 ms (90% CI: 6.7, 3.2), returning to base-
line level at 6 h.
The highest mean difference to time-matched placebo of
change of QTcF from average baseline (ΔΔQTcF) for all treat-
ments is summarized in Table 2.
Following i.v. administration of amisulpride 5 mg, the
ΔΔQTcF proﬁle demonstrated no changes of concern. At the
end of infusion (2 min), mean ΔΔQTcF was 3.6 ms (90% CI:
1.5, 5.8 ms), and the maximal mean ΔΔQTcF was 5.0 ms
(90% CI: 2.8, 7.1 ms), occurring at 8 min. The increase was
transient and at 30 min the mean difference was 2.1 ms
(90% CI: 0.1, 4.2 ms).
A 40mg infusion over 8min resulted in amean ΔΔQTcF of
7.9 ms (90% CI: 5.8, 10.0 ms) at 2 min and 23.4 ms (90% CI:
21.3, 25.5) at the end of the infusion (Table 2). The ΔΔQTcF
returned to below 5ms by 2 h andwas at baseline levels by 6 h
(Figure 2B).
After an oral dose of 400 mg moxiﬂoxacin, ΔΔQTcF was
unchanged until 2 h post-dose, then increased above 5ms be-
tween 3 h and 24 h post-dose, peaking at 4 h (12.3 ms; 90%
CI: 10.1, 14.6 ms) (Figure 2B). The Hochberg procedure ap-
plied to the results of the 2, 3 and 4 h time points showed a
statistically signiﬁcant difference between placebo and
moxiﬂoxacin (p < 0.001), conﬁrming study sensitivity. The
moxiﬂoxacin proﬁle was consistent with previous studies
where moxiﬂoxacin was administered in the fed and fasted
states, whereby the peak of the QTc effect is delayed if oral
moxiﬂoxacin is administered after a meal [23, 24].
In terms of heart rate on the ECG recordings, the largest
change from baseline for all treatments occurred at 24 h:
4.4 bpm for APD421 5 mg, 3.8 bpm for APD421 40 mg,
4.3 bpm for placebo and 4.6 bpm for moxiﬂoxacin. At the
8 min time point (end of infusion), heart rate was 64.6 bpm
after APD421 40 mg and 60.4 bpm after placebo. Change
from baseline for these two treatments at this time point
was 3.1 bpm and2.1 bpm, respectively, which is a difference
of about 5 bpm.
Categorical analysis
There were no absolute QTcF values >500 ms or QTcF values
>480 ms at any point during the study and no subjects had a
QTcF value >450 ms after administration of 5 mg
amisulpride. QTcF values >450 ms occurred with placebo
(n = 2), before administration of amisulpride (n = 1) and after
40 mg amisulpride administration, at the 8 min (n = 4) and
30 min (n = 2) time points. Moxiﬂoxacin QTcF values greater
than 450 ms were recorded in six occasions at 4 h (n = 1), 6 h
(n = 2), 12 h (n = 2) and 24 h (n = 1) after administration. QTcF
increases from baseline greater than 30 ms occurred at 8 min
(n = 4), 30 min (n = 1) and 90 min (n = 1) after the start of
infusion of 40 mg amisulpride.
Figure 2
(A) Mean change from average baseline (ΔQTcF) and (B) Time matched placebo corrected change from baseline (ΔΔQTcF). Amisulpride 5 mg
(T5) is represented by a black line, amisulpride 40 mg (T40) is represented by a red line, placebo is represented by a blue line and moxiﬂoxacin
400 mg by a brown line. The 90% CIs are shown as vertical lines and the threshold of 10 ms is shown as a horizontal line
Table 2
Maximum difference to time-matched placebo of change of QTcF from average baseline
90% CI
Treatment Time of peak effect(hh:mm) Mean SE Lower Upper
Amisulpride 5 mg 00:08 5.0 1.29 2.8 7.1
Amisulpride 40 mg 00:08 23.4 1.28 21.3 25.5
Moxiﬂoxacin 400 mg 04:00 12.3 1.37 10.1 14.6
SE: standard error. Based on a linear mixed effects model with treatment, sex and race as factors and average as covariate
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Pharmacokinetics
Table 3 summarizes the PK data for amisulpride. PK parame-
ters for both Caucasian and Japanese are also listed in
Table 3. Mean AUC0–∞, AUC0–t and Cmax values were consis-
tent with dose proportionality: at the 8-fold higher dose,
AUC0–∞ increased by approximately 9-fold, AUC0–t increased
by approximately 10-fold and Cmax increased by approxi-
mately 6.5-fold.
Concentration response analysis
The relationships between QTcF and the amisulpride plasma
concentration using all study subjects’ data and separated by
ethnicity are presented in Figure 3A and B, respectively. Slope
estimates of the effect of amisulpride together with a 90% CI,
p-values for the differences in slopes for Caucasian and
Japanese and predictions at the two concentrations are pre-
sented in Table 4.
At the geometric mean Cmax (169 ng ml
1 for 5 mg
amisulpride and 1276 ng ml1 for 40 mg), the predicted in-
crease in QTcF was 5.1 ms for the 5 mg dose and 24.4 ms for
40 mg, using a linear concentration effect model. The PK-PD
relationship was linear and dose proportional with no
differences between the ethnic groups, with neither the dif-
ference between slopes (p-value = 0.540) nor that between
intercepts for Caucasian and Japanese being statistically sig-
niﬁcant (Figure 3B). Predictions at 5 mg amisulpride also
showed no ethnic differences (p-value = 0.434). The
marginally signiﬁcant difference in the prediction at the
higher dose of amisulpide can be explained by the differ-
ences in pharmacokinetics as the differences in slopes to
only contribute minimally. Regression analysis of PK-PD
predicted that each additional increase of 10 ng ml1 in
plasma amisulpride concentration would lead to an increase
in QTcF of 0.175 ms. Mean PK (concentration) and PD
(placebo-corrected change from time-matched baseline)
time courses for the two doses of amisulpride suggested no
evidence of hysteresis.
Safety and tolerability
A total of 74 adverse events (AEs) were reported in 34 of 40
subjects, 8 with moxiﬂoxacin, 11 in the placebo arm, 12 with
5 mg amisulpride and 43 with 40 mg amisulpride. There were
no serious adverse events (SAEs), no AEs which led to with-
drawal and no AEs with severe intensity.
The most frequently reported treatment-emergent ad-
verse events (TEAEs) were infusion-related reactions reported
four times in the placebo group by two Caucasian and two
Japanese subjects, three times in the 5 mg amisulpride group
by one Caucasian subject and two Japanese, and 31 times in
the 40 mg amisulpride group by 16 Caucasians and 15
Japanese. The infusion-related reactions were a result of the
higher infusion rate. In general, infusion-related reactions
with amisulpride were essentially associated with site pain
and began as soon as the infusions started and lasted the
Table 3
Pharmacokinetic parameters for amisulpride following single intravenous doses of 5 mg and 40 mg amisulpride
Amisulpride 5 mg over 2 minMean (SD) Amisulpride 40 mg over 8 minMean (SD)
n 39 39
AUC0-∞ (ng ml
1 h1) 154.00 (30.17) 1374.14 (239.47)
AUC0-t (ng ml
1 h1) 134.59 (30.17) 1334.01 (228.36)
Cmax (ng ml
1) 200.49 (139.16) 1305.44 (329.35)
tmax (h)
a 0.033 (0.033–0.133) 0.133 (0.067–0.183)
t½ (h) 4.05 (0.78) 5.04 (0.66)
Caucasian
AUC0-∞ (ng ml
1 h1) 153.64 (35.04) 1376.79 (276.45)
AUC0-t (ng ml
1 h1) 133.12 (33.92) 1334.31 (261.55)
Cmax (ng ml
1) 186.33 (92.19) 1216.41 (229.37)
tmax (h)
a 0.033 (0.033–0.133) 0.133 (0.067–0.167)
t½ (h) 4.0056 (0.69) 5.0795 (0.69)
Japanese
AUC0-∞ (ng ml
1 h1) 154.44 (23.88) 1370.70 (189.37)
AUC0-t (ng ml
1 h1) 136.48 (25.39) 1333.63 (184.55)
Cmax (ng ml
1) 218.81 (184.94) 1420.65 (404.43)
tmax (h)
a 0.033 (0.033–0.133) 0.133 (0.133–0.183)
t½ (h) 4.11 (0.8918) 4.99 (0.6317)
aMedian (range) presented for tmax
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duration of the infusion, resolving within a fewminutes after
the end of infusion. In previous clinical studies with i.v.
amisulpride, infusion site reactions were also shown to be
short-lived and resolved when the infusion was slowed down
or stopped. Infusion-related reactions were not speciﬁc to any
ethnic group.
Most AEs were of Grade 1 on the CTCAE scale and of
mild intensity, with the exception of two events of Grade
2 (diarrhoea in one female Japanese subject and anxiety in
one male Caucasian subject) that were reported after 5 mg
amisulpride. These were isolated events and both resolved
without corrective therapy. There were no clinically relevant
changes in the laboratory parameters or physical examina-
tions in this study.
Discussion
This was the ﬁrst study to evaluate the effects of therapeutic
and supratherapeutic doses of an i.v. formulation of
amisulpride on cardiac repolarization in line with a speciﬁ-
cally designed TQT study performed according to ICH E14
[25]. The effect of moxiﬂoxacin on QTcF conﬁrmed the sensi-
tivity of the study to detect a relevant increase in QTcF. In
respect of a single i.v. dose of amisulpride at 5 mg, the study
met the criteria for a negative TQT study, with the upper
bound of 90% two-sided conﬁdence falling well below
10 ms. The effect of the 5 mg dose on the QT duration was
small and very short-lived, with values returning to pre-dose
levels within 30 min of administration. A more rapidly
Table 4
Slope estimates and predictions of amisulpride effect at 5 and 40 mg and differences between ethnic groups
Parameter Ethnicity Conc. (ng ml1) Estimate SE p-value 90% CI
Slope (ms (ng ml)) Caucasian 0.0169 0.0012 <0.001 0.0149 0.0190
Japanese 0.0180 0.0012 <0.001 0.0160 0.0200
Difference 0.0011 0.0017 0.540 0.0018 0.0039
Pred. at 5 mg (ms) Caucasian 160 4.6 0.9 <0.001 3.2 6.1
Japanese 181 5.6 0.9 <0.001 4.0 7.2
Difference 1.0 1.3 0.434 1.1 3.2
Pred. at 40 mg (ms) Caucasian 1206 22.3 1.6 <0.001 19.7 25.0
Japanese 1369 27.0 1.8 <0.001 24.0 30.0
Difference 4.7 2.4 0.056 0.7 8.7
Figure 3
Concentration-effect relationship. (A) Scatter plot of the placebo-corrected change in QTcF against the amisulpride plasma concentration
(ng ml1). The 90% CIs are represented by shades of grey; (B) PK-PD relationship by ethnicity. The regression lines for amisulpride derived
from a linear mixed effect model. The 90% CIs are represented by grey shading for the Japanese slope and red shading for the Caucasian
slope. The difference between the Caucasian and the Japanese is not statistically signiﬁcant (p-value = 0.540)
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infused eight-fold supratherapeutic dose of amisulpride did
cause a meaningful prolongation of the QT interval. None
of the subjects had QTcF values >500 ms or>480ms at either
dose; increases from baseline in QTc of >30 ms occurred only
with 40 mg amisulpride. Both doses were well tolerated by
Caucasian and Japanese subjects. The statistical analysis of
this study suggested that ethnicity has no inﬂuence on QT
response to amisulpride. Although the slopes of amisulpride
effect were not statistically signiﬁcant, the difference in the
predicted effect at 40 mg amisulpride was marginally signiﬁ-
cant. One limitation of this study is the fact that 12 of the
17 Japanese subjects weremale. Themost frequently reported
AE was pain in the arm during infusion which is dependent
on the rate of infusion and can bemostly avoided by reducing
the infusion speed.
The capability for hERG blockade has been shown as the
primary mechanism to predict QT prolongation associated
with antipsychotic drugs [26]. Amisulpride, in common with
some other substituted benzamides, was found to inhibit
hERG current with an IC50 of around 100 μM [15], a markedly
lower potency than some D2 antagonists. For example,
droperidol, a butyrophenone used both as an antipsychotic
and an antiemetic, has an IC50 two to three orders of greater,
at 32.2 nM [27]. Statistical models designed to predict the ex-
tent of QTc as a function of the blocking effects on hERG and
NaV1.5 may explain the QTc variability between antipsy-
chotic drugs, suggesting that inhibition of late INa can act as
a counterbalance of the effect of inhibition of IKr which can
have an effect on the drug’s pro-arrhythmic potential
triggered by hERG blockade [16]. However, the effect of
amisulpride on sodium channels remains to be fully
elucidated.
Literature on oral amisulpride used to treat psychiatric
disorders since its ﬁrst marketing authorization in 1986
supports amisulpride’s low propensity for clinical cardiac tox-
icity in practice. A review of 11 studies involving 1933 pa-
tients, of whom 905 had received amisulpride for acute
exacerbations of schizophrenia at a mean daily dose of
670 mg (range 100–1200) and 342 had received amisulpride
for predominant negative schizophrenia at a mean daily dose
of 118 mg, conﬁrmed the satisfactory cardiovascular safety
proﬁle of amisulpride. Overall, blood pressure variations were
devoid of clinical signiﬁcance and no arrhythmia was re-
ported [6]. The occurrence of torsade de pointes associated
with amisulpride has been reported [9–13]. However, all cases
are related to extremely large acute overdoses of amisulpride,
ranging from 4000–80 000 mg, leading to high plasma con-
centration of amisulpride. The plasma concentrations ob-
served in these cases are two to three orders of magnitude
above the mean Cmax plasma levels reported at the highest
dose in this study, indicating that the supratherapeutic dose
to treat PONV is not associated with torsade de pointes.
The predicted Cmax concentrations from the
concentration–response analysismodelﬁt were in close agree-
ment with the observed data in this study. The observed Cmax
values were 200 ngml1 and 1305 ngml1 for the 5 and 40mg
amisulpride doses, respectively. These ﬁndings are in agree-
ment with observed amisulpride plasma concentration levels
in schizophrenic patients ranging from20–1904 ngml1 after
oral administration of 150–1600 mg day1 of amisulpride
[28]. Additionally, plasma levels of 424 ng ml1 (SD
292.8 ngml1) were reported as therapeutic for schizophrenia
after an average daily dose of 772.3 mg (SD 346.7 mg)
amisulpride [28]. The largest available oral presentation of
amisulpride, a 400 mg tablet, was reported to deliver a Cmax
of approximately 1300 ng ml1 [29]. This is more than ﬁve
times higher than the Cmax of the 5 mg i.v. infusion and anal-
ogous to theCmax of the 40mg i.v. infusion. Regarding the use
of amisulpride as an anti-emetic, a bell-shaped dose–response
showed that a 5 mg dose is more effective than lower and
higher doses [20]. The Cmax of 200 ng ml
1 obtained after ad-
ministrationof 5mg amisulpride at 2.5mgmin1 in this study
can be associated with clinical effectiveness in the treatment
and prevention of PONV. Interestingly, therapeutic drug
monitoring has demonstrated that the plasma concentration
of approximately 200 ngml1 is associated with optimal clin-
ical response when oral doses of 400–800 mg day1 of
amisulpride are administered in schizophrenia and
schizoaffective disorder cases [30, 31].
The linear and proportional PK-PD relationship observed
indicated that the attained Cmax in this study is dependent
on dose and rate of infusion. However, this study investigated
only two dose regimens and two infusion rates, limiting
conclusions on the effects on QTcF of higher doses of
amisulpride administered at lower infusion rates; and, in
particular, the infusion rate which may be needed to avoid a
signiﬁcant QT/QTc interval prolongation with higher doses
of amisulpride.
In summary, this study shows that the proposed therapeu-
tic dose of 5 mg amisulpride for the management of PONV,
given intravenously over 2 min, is well tolerated by healthy
Caucasian and Japanese subjects and is not associated with
a QTcF prolongation of regulatory concern.
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